Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
Izanne RoosEmmanuelle LerayRomain CaseyDana HorakovaEva HavrdovaGuillermo IzquierdoSara Eichau MadueñoFrancesco PattiGilles EdanMarc DebouverieJean PelletierSerkan OzakbasMaria Pia AmatoPierre ClavelouPierre GrammondCavit BozKatherine BuzzardOlga SkibinaJonathan CironOliver GerlachFrancois Grand'MaisonJeannette Lechner-ScottCharles MalpasHelmut ButzkuevenSandra VukusicTomas Kalinciknull nullPublished in: Neurology (2021)
This study provides Class III evidence that high-efficacy therapy is superior to low-efficacy therapy in reducing relapses in patients with active SPMS, although we did not find a difference in disability progression between patients treated with high- and low-efficacy therapy.